Oklahoma State Basketball

Oklahoma State Snaps Five-Game Losing Streak With 91-84 Overtime Win Over West Virginia

The Cowboys also snapped an eight-game losing streak in overtime games.
February 24, 2026
253 Views
Discuss
Story Poster
Photo by William Purnell-Imagn Images

STILLWATER – Oklahoma State snapped two losing streaks with the 91-84 win over West Virginia on Tueday night, a current five-game losing streak, which dates back to the road loss to Arizona, and an eight-game losing streak in overtime games. The last overtime win for the Pokes was an 82-79 win over Kansas State back on February 19, 2022. 

With the win, the Cowboys improved to 17-11 overall on the season and 5-10 in Big 12 play. 

One of the impressive aspects of this game is that the Mountaineers were allowing just 66 points per game and this was the most points WVU had allowed since an 88-point performance by Arizona back on January 24.

The Cowboys had one of their best offensive games of the past month against the Mountaineers. As a team the Cowboys shot 49% from the floor, 43% from 3-point range and 70% from the free throw line on 19-of-27 shooting. They outrebounded WVU 40-33 and forced 11 turnovers for 15 points on the other end.

Parsa Fallah led the way for the Pokes with 18 points on 7-of-12 shooting from the floor and a team-high eight rebounds. He unfortunately left the game late with an apparent left knee injury after a breakaway dunk on an inbounds play to seal the game. The extent of his injury is unknown at this time, but he had to be wheeled off the court. 

Kanye Clary had 17 points and a team-high six assists, Jaylen Curry had 15 points on 5-of-6 shooting from the floor and 3-for-3 from 3-point range, Andrija Vukovic finished with 12 points and both Christian Coleman and Anthony Roy finished with 10 points each.

The Cowboys are back in action this coming Saturday as they travel out to face Cincinnati on Saturday at 1 p.m.

Discuss
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.